Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.
DOWNLOAD NOWNerandomilast is an inhibitor of phosphodiesterase 4B (PDE4B; IC50 = 0.01 µM).1 It is selective for PDE4B over PDE4A, PDE4C, and PDE4D (IC50s = 0.248, 8.7, and 0.091 µM, respectively), PDE7A, PDE3A, PDE1C, and PDE9A (IC50s = 14, 120, 46, and >100 µM, respectively), and does not inhibit PDE2A, PDE5, or PDE6. Nerandomilast inhibits LPS-induced TNF-α release and phytohemagglutinin P-induced IL-2 release in isolated human peripheral blood mononuclear cells (PBMCs; IC50s = 0.035 and 0.009 µM, respectively). It exhibits a lower emetic potential than roflumilast (Item No. 15141) in Asian house shrews. Nerandomilast (12.5 mg/kg) reduces decreases in forced vital capacity and static lung volume in a mouse model of pulmonary fibrosis bleomycin-induced. Formulations containing nerandomilast have been used in the treatment of idiopathic pulmonary fibrosis.
WARNING This product is not for human or veterinary use.
1. BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis. Front. Pharmacol. 13, 838449 (2022).